PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins

Intrinsic and acquired tumor drug resistance limits the therapeutic efficacy of camptothecins (CPTs). Downregulation of the mitotic kinase PLK1 was found associated with apoptosis induced by SN38 (CPT11 active metabolite). We investigated the role of PLK1 in the cell response to CPTs in squamous cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuco, Valentina, De Cesare, Michelandrea, Zaffaroni, Nadia, Lanzi, Cinzia, Cassinelli, Giuliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496180/
https://www.ncbi.nlm.nih.gov/pubmed/25826089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496180/
https://www.ncbi.nlm.nih.gov/pubmed/25826089

Ejemplares similares